Updated Jul 16, 2026
Nijdam Anna has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $307K.
Anna Nijdam is associated with Pharvaris N.V., a biopharmaceutical company focused on developing treatments for hereditary angioedema. Specific details about her role and contributions to the company are not widely documented.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-08 | PHVS | Pharvaris N.V. | S — Open-market sale | 2.7K | $30.87 | $82K |
| 2026-05-26 | PHVS | Pharvaris N.V. | S — Open-market sale | 5.5K | $30.74 | $169K |
| 2026-05-26 | PHVS | Pharvaris N.V. | M — Option exercise | 5.5K | $20.00 | $110K |
| 2026-05-26 | PHVS | Pharvaris N.V. | S — Open-market sale | 1.8K | $30.60 | $56K |
| 2026-05-26 | PHVS | Pharvaris N.V. | M — Option exercise | 1.8K | $20.00 | $37K |
| 2026-04-14 | PHVS | Pharvaris N.V. | F — Tax withholding / forfeiture | 548 | $26.63 | $15K |
| 2026-04-08 | PHVS | Pharvaris N.V. | F — Tax withholding / forfeiture | 1.2K | $28.56 | $33K |
| 2026-04-03 | PHVS | Pharvaris N.V. | F — Tax withholding / forfeiture | 1.2K | $28.25 | $33K |
Anna Nijdam is associated with Pharvaris N.V., a biopharmaceutical company focused on developing treatments for hereditary angioedema. Specific details about her role and contributions to the company are not widely documented.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($307K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Nijdam Anna profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.